| Literature DB >> 21152057 |
Bart J Currie1, Linda Ward, Allen C Cheng.
Abstract
BACKGROUND: Over 20 years, from October 1989, the Darwin prospective melioidosis study has documented 540 cases from tropical Australia, providing new insights into epidemiology and the clinical spectrum. PRINCIPALEntities:
Mesh:
Year: 2010 PMID: 21152057 PMCID: PMC2994918 DOI: 10.1371/journal.pntd.0000900
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Risk factors for 540 patients with melioidosis.
| Patients | Deaths | |||
| Risk factor | n | % of total | n | % who died |
| Diabetes | 213 | 39% | 33 | 15% |
| Hazardous alcohol use | 211 | 39% | 33 | 16% |
| Chronic lung disease | 140 | 26% | 27 | 19% |
| Chronic renal disease | 65 | 12% | 13 | 20% |
| Rheumatic heart disease and/or congestive cardiac failure | 39 | 7% | 9 | 23% |
| Malignancy | 31 | 6% | 8 | 26% |
| Immunosuppressive therapy and other immunosuppression | 31 | 6% | 6 | 20% |
| Kava use | 27 | 5% | 4 | 15% |
| Other | 6 | 1% | 2 | 33% |
| No risk factors | 106 | 20% | 2 | 2% |
Mostly patients taking prednisolone therapy. Two with HIV infection and 1 with HTLV-I infection.
Three with hepatitis B-related chronic liver disease, 1 with hemochromatosis and chronic liver disease, 1 with other chronic liver disease and 1 with multiple strokes and prior aspiration pneumonia.
Both elderly; ages 75 and 82 years old but no other apparent risk factors for melioidosis.
Not significant in comparison to those without the risk factor.
Risk ratio = 1.5 (95% CI 1.1–2.4) in comparison to those without chronic lung disease; p = 0.048.
Risk ratio = 0.11 (95%CI 0.03–0.44) in comparison to presence of any risk factor; p<0.001.
Clinical presentations and outcomes of 540 cases of melioidosis.
| Total | Bacteremic | Non-bacteremic | ||||
| Number | Deaths (Mortality) | Number | Deaths (Mortality) | Number | Deaths (Mortality) | |
|
|
|
|
|
|
|
|
| Pneumonia | 88 | 43 (49%) | 78 | 35 (45%) | 10 | 8 (80%) |
| No evident focus | 13 | 8 (62%) | 12 | 7 (58%) | 1 | 1 (100%) |
| Genitourinary | 10 | 5 (50%) | 9 | 4 (44%) | 1 | 1 (100%) |
| Osteomyelitis/septic arthritis | 4 | 2 (50%) | 4 | 2 (50%) | 0 | 0 (0%) |
| Soft tissue abscess | 1 | 0 (0%) | 0 | 0 | 1 | 0 (0%) |
|
|
|
|
|
|
|
|
| Pneumonia | 190 | 12 (6%) | 89 | 9 (10%) | 101 | 3 (3%) |
| Skin infection | 68 | 0 (0%) | 1 | 0 (0%) | 67 | 0 (0%) |
| Genitourinary | 66 | 2 (3%) | 41 | 2 (5%) | 25 | 0 (0%) |
| No evident focus | 52 | 2 (4%) | 47 | 2 (4%) | 5 | 0 (0%) |
| Soft tissue abscess(es) | 18 | 0 (0%) | 4 | 0 (0%) | 14 | 0 (0%) |
| Osteomyelitis/septic arthritis | 16 | 0 (0%) | 10 | 0 (0%) | 6 | 0 (0%) |
| Neurological | 14 | 3 (21%) | 3 | 0 (0%) | 11 | 3 (27%) |
|
|
|
|
|
|
|
|
7 blood cultures not done, 3 blood cultures negative.
Culture +ve for B. pseudomallei only from rectal swab, although fatal septic shock.
blood culture not done.
Risk factors in 278 patients presenting with melioidosis pneumonia.
| Patients | Primary Pneumonia | Univariate | Multivariate | |||||||
| n | % | n | % | p | OR | 95% CI | p | OR | 95% CI | |
|
| ||||||||||
| No | 277 | 51% | 130 | 47% | ns | |||||
| Yes | 263 | 49% | 148 | 56% | 0.030 | 1.3 | (1.04–2.0) | |||
|
| ||||||||||
| No | 327 | 61% | 156 | 48% | ns | |||||
| Yes | 213 | 39% | 122 | 57% | 0.030 | 1.5 | (1.04–2.1) | |||
|
| ||||||||||
| No | 329 | 61% | 154 | 47% | ||||||
| Yes | 211 | 39% | 124 | 59% | 0.007 | 1.6 | (1.1–2.3) | 0.041 | 1.5 | (1.02–2.1) |
|
| ||||||||||
| No | 400 | 74% | 181 | 45% | ||||||
| Yes | 74 | 26% | 97 | 69% | <0.001 | 1.5 | (1.3–1.8) | <0.001 | 2.5 | (1.6–3.9) |
|
| ||||||||||
| No | 501 | 93% | 248 | 50% | ||||||
| Yes | 39 | 7% | 30 | 77% | 0.001 | 3.4 | (1.6–7.2) | 0.009 | 2.8 | (1.3–6.2) |
|
| ||||||||||
| No | 513 | 95% | 272 | 53% | ||||||
| Yes | 27 | 5% | 6 | 22% | 0.002 | 0.3 | (0.1–0.6) | 0.004 | 0.2 | (0.1–0.6) |
RHD/CCF; rheumatic heart disease and/or congestive cardiac failure.
ns; not significant.
Internal organ abscesses and other foci of infection in 540 patients with melioidosis.
| Site | n | % |
| Prostatic abscess(es) | 76 | 20% |
| Splenic abscess(es) | 28 | 5% |
| Kidney abscess(es) | 18 | 3% |
| Liver abscess(es) | 15 | 3% |
| Adrenal abscess | 3 | <1% |
| Psoas abscess(es) | 4 | <1% |
| Other muscle abscess/myositis | 8 | 1% |
| Cellulitis | 3 | <1% |
| Lymphadenitis | 9 | 2% |
| Mediastinal mass | 17 | 3% |
| Pericarditis | 4 | <1% |
| Para-intestinal mass | 4 | <1% |
| Mastitis | 3 | <1% |
| Epididymo-orchitis | 3 | <1% |
| Mycotic (pseudo)aneurysm | 2 | <1% |
calculated for males only.
Secondary clinical foci for major primary diagnostic groups.
| Primary diagnosis | Total number | Number with secondary foci (% of total) | More common secondary foci |
| Pneumonia | 278 | 41 (15%) | 17 prostatic abscesses, 10 splenic abscesses, 7 septic arthritis, 6 neurological, 6 liver abscesses, 5 renal abscesses |
| Genitourinary | 76 | 26 (34%) | 17 pneumonia, 3 splenic abscesses, 2 liver abscesses |
| Skin infection | 68 | 6(9%) | 3 pneumonia, 2 splenic abscesses, 2 liver abscesses |
| Bacteremia, no initial focus | 59 | 25 (42%) | 13 pneumonia, 6 splenic abscesses, 4 septic arthritis, 3 prostatic abscesses, 2 liver abscesses, 2 osteomyelitis, 2 neurological, 1 renal abscess |
| Osteomyelitis/septic arthritis | 20 | 11 (55%) | 6 pneumonia, 3 splenic abscesses |
| Soft tissue abscess(es) | 19 | 9 (47%) | 3 pneumonia, 2 septic arthritis, 2 osteomyelitis, 2 splenic abscesses |
| Neurological melioidosis | 14 | 5 (36%) | 3 pneumonia |
more than 1 secondary focus found in some cases.
Changing outcomes over the 20 years.
| First 5 years | Second 5 years | Third 5 years | Fourth 5 years | Total over 20 years | |
| Number | 88 | 164 | 139 | 149 | 540 |
| Died (%) | 26 (30%) | 24 (15%) | 14 (10%) | 13 (9%) | 77 (14%) |
| Blood culture +ve (% of total) | 40 (45%) | 77 (47%) | 83 (60%) | 98 (66%) | 298 (55%) |
| Septic shock (% of total) | 16 (18%) | 28 (17%) | 39 (28%) | 33 (22%) | 116 (21%) |
| Septic shock and died (% mortality) | 16 (100%) | 21 (75%) | 12 (31%) | 9 (27%) | 58 |
| Ventilated (% of total) | 8 (9%) | 22 (13%) | 34 (24%) | 33 (22%) | 97 (18%) |
| Ventilated and died (% mortality) | 8 (100%) | 16 (73%) | 8 (24%) | 9 (27%) | 41 |
| Median age (years) | 51y | 49y | 49y | 49y | 49y |
| Indigenous (%) | 40 (45%) | 90 (55%) | 63 (45%) | 87 (59%) | |
| Diabetic (%) | 37 (42%) | 56 (34%) | 55 (40%) | 65 (44%) | 213 (39%) |
| No risk factors | 15 (17%) | 39 (24%) | 26 (19%) | 26 (17%) | 106 (20%) |
Significant trend for lower mortality over time; p<0.001 Chi-squared test of trend for proportion.
Significant trend for lower mortality over time; p = 0.002 Chi-squared test of trend for proportion.
Associations with bacteremia.
| Patients | Bacteremic | Univariate | Multivariate | |||||||
|
| % |
| % |
| OR | 95% CI |
| OR | 95% CI | |
|
| ||||||||||
| No | 259 | 48% | 112 | 44% | ||||||
| Yes | 281 | 52% | 186 | 67% | <0.001 | 2.7 | (1.9–3.8) | <0.001 | 3.2 | (2.1–4.9) |
|
| ||||||||||
| No | 277 | 51% | 131 | 48% | ||||||
| Yes | 263 | 49% | 167 | 64% | <0.001 | 1.9 | (1.4–2.7) | <0.001 | 2.3 | (1.5–3.6) |
|
| ||||||||||
| No | 327 | 61% | 152 | 47% | ||||||
| Yes | 213 | 39% | 146 | 70% | <0.001 | 2.6 | (1.8–3.7) | <0.001 | 2.2 | (1.4–3.2) |
|
| ||||||||||
| No | 329 | 61% | 166 | 51% | ||||||
| Yes | 211 | 39% | 132 | 64% | 0.004 | 1.7 | (1.2–2.4) | 0.014 | 1.6 | (1.1–2.4) |
|
| ||||||||||
| No | 475 | 88% | 247 | 53% | ||||||
| Yes | 65 | 12% | 51 | 78% | <0.001 | 3.2 | (1.8–6.0) | 0.019 | 2.2 | (1.1–4.3) |
|
| ||||||||||
| No | 509 | 94% | 274 | 55% | ||||||
| Yes | 31 | 6% | 24 | 77% | 0.013 | 2.8 | (1.2–6.6) | 0.003 | 4.1 | (1.6–11) |
|
| ||||||||||
| No | 509 | 94% | 275 | 55% | ||||||
| Yes | 31 | 6% | 23 | 75% | 0.036 | 2.4 | (1.1–5.3) | 0.028 | 2.7 | (1.1–6.5) |
Associations with mortality.
| Patients | Deaths | Univariate | Multivariate | |||||||
|
| % |
| % died | p | OR | 95% CI | p | OR | 95% CI | |
|
| ||||||||||
| No | 277 | 51% | 26 | 9% | ||||||
| Yes | 263 | 49% | 51 | 19% | 0.001 | 2.3 | (1.4–3.9) | 0.009 | 2.0 | (1.2–3.3) |
|
| ||||||||||
| No | 259 | 48% | 36 | 14% | ns | ns | ||||
| Yes | 281 | 52% | 41 | 15% | ||||||
|
| ||||||||||
| Urban Darwin | 262 | 49% | 43 | 16% | ||||||
| Rural Darwin | 65 | 12% | 5 | 8% | ns | ns | ||||
| Remote | 169 | 31% | 22 | 13% | ||||||
| Other | 44 | 8% | 7 | 16% | ||||||
|
| ||||||||||
| Mar–Nov | 260 | 48% | 28 | 11% | 0.025 | 1.8 | (1.1–2.9) | ns | ||
| Dec–Feb | 280 | 52% | 49 | 18% | ||||||
|
| ||||||||||
| None | 106 | 20% | 2 | 2% | ||||||
| Any | 434 | 80% | 75 | 17% | <0.001 | 11 | (2.6–45) | 0.002 | 9.4 | (2.3–39) |
Risk factors; as listed in Table 1.
ns; not significant.